NSE: CONCORDBIO · 27 October 2026
- Concord Biotech has risen 10.40% over 2 trading sessions; today's move is +3.51%.
- Concord Biotech submitted the Scrutinizer's report and voting results for its postal ballot concluded on October 24, 2026. Shareholders overwhelmingly approved the increase in authorized share capital from ₹11 crore to ₹22 crore and the issuance of 1:1 bonus equity shares.
- Trading volume was 1.01 times the 20-day average daily volume.
Concord Biotech share price: 10.40% rise over 2 trading sessions
Concord Biotech Ltd. shares advanced 3.51% on Tuesday, closing the session at ₹1,357.20 after moving between an intraday low of ₹1,299.10 and a high of ₹1,362.50.
The broader pharmaceutical sector exhibited strength, with the Nifty Pharma sector benchmark gaining 2.06% on the trading day while the headline Nifty index edged down marginally by 0.02%. Concord Biotech's upward move coincided with positive momentum within the broader pharma sector, outperforming the flat broader market even as the stock continues to navigate a 20-day return of -6.63% alongside a 5-day return of 5.55%.
In recent corporate updates, the company announced the voting results and Scrutinizer's report for its postal ballot on October 26, 2026, where shareholders approved increasing the authorized share capital and issuing a 1:1 bonus equity share issue. Additionally, the company successfully concluded a USFDA inspection at its Unit II formulation facility in Valthera with a single minor procedural observation on September 18, 2026, though no direct causal link connects these previous disclosures to today's specific price movement.
95,522 shares traded by 27 October 2026 · 02:55 PM IST. This compares with a 20-day average daily volume of 94,569 shares (1.01 times). The five-day average daily volume was 1.08 lakh shares. Separately, the NSE report for 26 October 2026 showed 47,354 shares delivered, representing 25.53% of that day’s traded volume. The same report recorded 32,622 trades.
The upward price action lacks a specific same-day catalyst, aligning instead with positive momentum across the broader pharmaceutical sector and ongoing recovery from recent pullbacks.
Latest Company Developments
Concord Biotech submitted the Scrutinizer's report and voting results for its postal ballot concluded on October 24, 2026. Shareholders overwhelmingly approved the increase in authorized share capital from ₹11 crore to ₹22 crore and the issuance of 1:1 bonus equity shares.
The formal approval clears the structural path for executing the 1:1 bonus share allotment, doubling the paid-up equity base.
The US Food and Drug Administration completed an inspection at the company's Unit II formulation facility in Valthera, Gujarat. The inspection concluded with one minor procedural observation that was not related to good manufacturing practices.
The company stated that the minor observation is procedural and is not expected to have any material impact on current business operations or supplies.
Concord Biotech's Board of Directors approved the issuance of bonus equity shares in the proportion of 1:1, capitalizing ₹10.46 crore from the securities premium account. The pre-bonus paid-up capital of ₹10.46 crore will expand to ₹20.92 crore post-bonus.
Bonus issuances increase liquidity and widen retail accessibility by expanding the total share count.
Concord Biotech Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
Concord Biotech Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 5.84% on 30 September 2026. This compares with 4.40% on 30 June 2026, a change of +1.44 percentage points.
The filing reported 22 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution and record date announcement for the approved 1:1 bonus share issue
- Upcoming financial results for the quarter and half year ended September 30, 2026
- Progress on regulatory responses to the USFDA facility observation
- Delivery volume trends and institutional participation levels
More Concord Biotech news and dated analysis →
Frequently Asked Questions
What is the latest Concord Biotech company news?
Concord Biotech submitted the Scrutinizer's report and voting results for its postal ballot concluded on October 24, 2026. Shareholders overwhelmingly approved the increase in authorized share capital from ₹11 crore to ₹22 crore and the issuance of 1:1 bonus equity shares.
How strong was Concord Biotech’s trading volume?
95,522 shares traded, 1.01 times the 20-day average daily volume. The price and volume data are dated 27 October 2026 · 02:55 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.